Based on the current evidence, which highlights the lack of a clear direct cytotoxic effect of small molecule DDAH1 inhibitors, it would appear that the best therapeutic window is within the early stages of cancer development, typically driven by neovascularization, in order to timely prevent dissemination and metastasis. The gene discussed is DDAH1; the disease is cancer.